Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-24-014747
Filing Date
2024-11-07
Accepted
2024-11-07 07:02:27
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 6-K tmb-20240930x6k.htm 6-K 22936
2 EX-99.1 tmb-20240930xex99d1.htm   iXBRL EX-99.1 870859
3 EX-99.2 tmb-20240930xex99d2.htm EX-99.2 447020
  Complete submission text file 0001558370-24-014747.txt   4131095

Data Files

Seq Description Document Type Size
4 EX-101.SCH tmb-20240930.xsd EX-101.SCH 51149
5 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 45203
6 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 128321
7 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 300571
8 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 230050
73 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930xex99d1_htm.xml XML 480606
Mailing Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK
Business Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK 31 88 166 7000
ProQR Therapeutics N.V. (Filer) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36622 | Film No.: 241433076
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)